Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPIRED III: Alkaline phosphatase to prevent ischemic kidney injury and systemic inflammation in cardiac surgery
2016-002663-33Phase 3Active
- Sponsor
- Alloksys Life Sciences
- Start
- Sep 2016
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of bovine intestinal alkaline phosphatase in acute kidney failure (AKF), Systemic Inflammatory Response Syndrome (SIRS) and Postcardiac surgery functional disturbance, sponsored by Alloksys Life Sciences. Primary endpoint: Incidence and extent of acute kidney injury after cardiopulmonary bypass. Started Sep 2016; status: active.
02
Drugs
bovine intestinal alkaline phosphatase
03
Conditions
acute kidney failure (AKF)Systemic Inflammatory Response Syndrome (SIRS)Postcardiac surgery functional disturbance
Beyond the preview
Go deeper on 2016-002663-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002663-33.